文献速递血栓与止血白血病

急性淋巴细胞白血病中的血栓栓塞:NOPHO ALL2008方案治疗1至45岁患者的结果

Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
PubMed 文献 · Blood · 2018-04-16

该研究前瞻性登记了1772例1至45岁接受NOPHO ALL2008方案治疗的急性淋巴细胞白血病患者的血栓栓塞事件。2.5年累积发生率为7.9%,年龄≥10岁和纵隔肿块与风险增加相关,血栓栓塞诊断与复发风险增加无关,5例死亡归因于血栓栓塞,年龄≥10岁患者可考虑预防性抗血栓治疗。

要点

  • 2.5年血栓栓塞累积发生率为7.9%(95%CI 6.6-9.1),年龄≥10岁患者更高(P<.0001)。
  • 年龄10.0-17.9岁(HRa 4.9)和18.0-45.9岁(HRa 6.06)及纵隔肿块(HRa 2.1)与风险增加相关。
  • 血栓栓塞诊断与复发风险增加无关(P=.6),5例死亡归因于血栓栓塞。

核心结论

  • 年龄≥10岁的患者可考虑预防性抗血栓治疗,但年龄≥10岁、淋巴结肿大和纵隔肿块的预测价值尚需在另一队列中验证。

研究设计与样本

  • 前瞻性登记研究,纳入2008年7月至2017年4月接受NOPHO ALL2008方案治疗的1772例连续北欧/波罗的海地区1至45岁急性淋巴细胞白血病患者。

主要发现

  • 2.5年血栓栓塞累积发生率为7.9%(95%CI 6.6-9.1),年龄≥10岁患者更高(P<.0001)。
  • 调整后风险比:年龄10.0-17.9岁HRa 4.9(95%CI 3.1-7.8,P<.0001),18.0-45.9岁HRa 6.06(95%CI 3.65-10.1,P<.0001),诊断时纵隔肿块HRa 2.1(95%CI 1.0-4.3,P=.04)。
  • 多绝对风险回归模型:年龄≥10岁绝对风险比RR 4.7(95%CI 3.1-7.1),淋巴结肿大RR 2.0(95%CI 1.2-3.1),纵隔肿块RR 1.6(95%CI 1.0-2.6)。
  • 与小于10.0岁儿童相比,18.0-45.9岁患者肺栓塞风险增加(HRa 11.6,95%CI 4.02-33.7,P<.0001),10.0-17.9岁患者脑静脉窦血栓风险增加(HRa 3.3,95%CI 1.5-7.3,P=.003)。
  • 128例血栓栓塞患者中38例天冬酰胺酶治疗被截断,血栓栓塞诊断与复发风险增加无关(P=.6);5例死亡归因于血栓栓塞,<18.0岁血栓栓塞患者较同龄无血栓栓塞患者死亡风险增加(两者P≤.01)。

临床怎么用

  • 年龄≥10岁患者可考虑预防性抗血栓治疗(作者结论)。

局限性

  • 年龄≥10岁、淋巴结肿大和纵隔肿块的预测价值尚需在另一队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thromboembolism frequently occurs during acute lymphoblastic leukemia (ALL) therapy. We prospectively registered thromboembolic events during the treatment of 1772 consecutive Nordic/Baltic patients with ALL aged 1 to 45 years who were treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol (July 2008-April 2017). The 2.5-year cumulative incidence of thromboembolism (N = 137) was 7.9% (95% confidence interval [CI], 6.6-9.1); it was higher in patients aged at least 10 years (P < .0001). Adjusted hazard ratios (HRas) were associated with greater age (range, 10.0-17.9 years: HRa, 4.9 [95% CI, 3.1-7.8; P < .0001]; 18.0-45.9 years: HRa, 6.06 [95% CI, 3.65-10.1; P < .0001]) and mediastinal mass at ALL diagnosis (HRa, 2.1; 95% CI, 1.0-4.3; P = .04). In a multiple absolute risk regression model addressing 3 thromboembolism risk factors, age at least 10 years had the largest absolute risk ratio (RRage, 4.7 [95% CI, 3.1-7.1]; RRenlarged lymph nodes, 2.0 [95% CI, 1.2-3.1]; RRmediastinal mass, 1.6 [95% CI, 1.0-2.6]). Patients aged 18.0 to 45.9 years had an increased hazard of pulmonary embolism (HRa, 11.6; 95% CI, 4.02-33.7; P < .0001), and patients aged 10.0 to 17.9 years had an increased hazard of cerebral sinus venous thrombosis (HRa, 3.3; 95% CI, 1.5-7.3; P = .003) compared with children younger than 10.0 years. Asparaginase was truncated in 38/128 patients with thromboembolism, whereas thromboembolism diagnosis was unassociated with increased hazard of relapse (P = .6). Five deaths were attributable to thromboembolism, and patients younger than 18.0 years with thromboembolism had increased hazard of dying compared with same-aged patients without thromboembolism (both P ≤ .01). In conclusion, patients aged at least 10 years could be candidates for preemptive antithrombotic prophylaxis. However, the predictive value of age 10 years or older, enlarged lymph nodes, and mediastinal mass remain to be validated in another cohort.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018. PMID: 29661787. doi:10.1182/blood-2018-01-827949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。